Unknown

Dataset Information

0

Germline genetic predictors of aromatase inhibitor concentrations, estrogen suppression and drug efficacy and toxicity in breast cancer patients.

ABSTRACT: The third-generation aromatase inhibitors (AIs), anastrozole, letrozole and exemestane, are highly effective for the treatment of estrogen receptor-positive breast cancer in postmenopausal women. AIs inhibit the aromatase (CYP19A1)-mediated production of estrogens. Most patients taking AIs achieve undetectable blood estrogen concentrations resulting in drug efficacy with tolerable side effects. However, some patients have suboptimal outcomes, which may be due, in part, to inherited germline genetic variants. This review summarizes published germline genetic associations with AI treatment outcomes including systemic AI concentrations, estrogenic response to AIs, AI treatment efficacy and AI treatment toxicities. Significant associations are highlighted with commentary about prioritization for future validation to identify pharmacogenetic predictors of AI treatment outcomes that can be used to inform personalized treatment decisions in patients with estrogen receptor-positive breast cancer.

SUBMITTER: Hertz DL 

PROVIDER: S-EPMC6219438 | biostudies-literature | 2017 Apr

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Germline genetic predictors of aromatase inhibitor concentrations, estrogen suppression and drug efficacy and toxicity in breast cancer patients.

Hertz Daniel L DL   Henry N Lynn NL   Rae James M JM  

Pharmacogenomics 20170327 5

The third-generation aromatase inhibitors (AIs), anastrozole, letrozole and exemestane, are highly effective for the treatment of estrogen receptor-positive breast cancer in postmenopausal women. AIs inhibit the aromatase (CYP19A1)-mediated production of estrogens. Most patients taking AIs achieve undetectable blood estrogen concentrations resulting in drug efficacy with tolerable side effects. However, some patients have suboptimal outcomes, which may be due, in part, to inherited germline gene  ...[more]

Similar Datasets

Unknown Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in post-menopausal breast cancer patients.
| S-EPMC5709190 | biostudies-literature
Unknown Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer.
| S-EPMC7238733 | biostudies-literature
Unknown Prospective assessment of patient-reported outcomes and estradiol and drug concentrations in patients experiencing toxicity from adjuvant aromatase inhibitors.
| S-EPMC5517133 | biostudies-literature
Unknown Estrogen receptors ? and ? and aromatase as independent predictors for prostate cancer outcome.
| S-EPMC5017140 | biostudies-literature
Unknown Predictors of recovery of ovarian function during aromatase inhibitor therapy.
| S-EPMC3718506 | biostudies-literature
Unknown Ruxolitinib and exemestane for estrogen receptor positive, aromatase inhibitor resistant advanced breast cancer.
| S-EPMC9652412 | biostudies-literature
Genomics,Multiomics Estrogen Receptor Positive Breast Cancer: Aromatase Inhibitor Response Study
| phs000472.v1.p1 | EGA
Unknown Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast cancer.
| S-EPMC3646626 | biostudies-literature
Unknown Expression of estrogen-related gene markers in breast cancer tissue predicts aromatase inhibitor responsiveness.
| S-EPMC3819361 | biostudies-literature
Unknown Inhibitory effect of chrysin on estrogen biosynthesis by suppression of enzyme aromatase (CYP19): A systematic review.
| S-EPMC7063143 | biostudies-literature